Scanning Pharma Equities - Novo Nordisk, Teva Pharma Industries, Sanofi, Valeant Pharma Intl., and Eli Lilly

LONDON, September 26, 2014 /PRNewswire/ --

On Thursday, September 25, 2014, the NASDAQ Composite ended at 4,466.75, down 1.94%, the Dow Jones Industrial Average finished the day 1.54% lower at 16,945.80, and the S&P 500 closed at 1,965.99, down 1.62%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 743.47, down 1.58%, while the index has advanced 4.99% in the last three months. Investor-Edge has initiated coverage on the following equities: Novo Nordisk A/S (NYSE: NVO), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Sanofi (NYSE: SNY), Valeant Pharmaceuticals International Inc. (NYSE: VRX), and Eli Lilly and Company (NYSE: LLY). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

Shares in Novo Nordisk A/S finished Thursday's session 0.46% lower at $47.78. A total of 0.73 million shares were traded, which was below its three months average volume of 0.95 million shares. The stock moved between $47.60 and $48.13 during the session. Over the last one month and the previous three months, Novo Nordisk A/S's shares have advanced 4.99% and 4.39%, respectively. Additionally, from the beginning of 2014, the stock has gained an upside of 29.30%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $45.89 is greater than its 200-day moving average of $43.53. Novo Nordisk A/S's stock has a Relative Strength Index (RSI) of 61.49. Sign up and read the free notes on NVO at:

www.Investor-Edge.com/NVO-26Sep2014

On Thursday, shares in Teva Pharmaceutical Industries Ltd. traded between $53.28 and $54.00 before ending the session 0.52% lower at $53.46. The stock reported a trading volume of 3.19 million shares, below its three months average volume of 3.69 million shares. Teva Pharmaceutical Industries Ltd.'s shares have advanced 4.72% in the previous three trading sessions, 2.35% in the last one month and 33.38% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $52.69 and $49.26, respectively. Moreover, shares of Teva Pharmaceutical Industries Ltd have an RSI of 58.68. The complimentary notes on TEVA can be downloaded as in PDF format at:

www.Investor-Edge.com/TEVA-26Sep2014

Sanofi's stock declined 1.90%, to close the day at $55.85. The stock recorded a trading volume of 1.11 million shares, close to its three months average volume of 1.07 million shares. The stock oscillated between $55.41 and $56.69 during the session. Over the last one month and over the past three months, Sanofi's shares have gained 3.97% and 4.39%, respectively. Further, the stock has gained 4.14% since the start of this year. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $53.81 is above its 200-day moving average of $52.33. Additionally, Sanofi has an RSI of 60.97. Register for free on Investor-Edge and access the latest research on SNY at:

www.Investor-Edge.com/SNY-26Sep2014

On Thursday, shares in Valeant Pharmaceuticals International Inc. recorded a trading volume of 5.61 million shares, higher than its three months average volume of 2.51 million shares. The stock ended the day at $127.80, which was 3.06% above its previous day's closing of $124.00, and registered an intraday range of $126.22 and $131.87. Shares of the company traded at a PE ratio of 387.27. Valeant Pharmaceuticals International Inc.'s shares have surged 9.91% in the previous three trading sessions, 10.67% in the last one month and 8.86% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $117.70 and $126.34, respectively. Furthermore, shares of Valeant Pharmaceuticals International Inc. have an RSI of 61.63. The complete research on VRX is available for free at:

www.Investor-Edge.com/VRX-26Sep2014

Eli Lilly and Co.'s stock edged 0.92% lower, to close Thursday's session at $65.58, after oscillating between $65.50 and $66.14. The stock recorded a trading volume of 3.11 million shares, below its three months average volume of 3.71 million shares. Eli Lilly and Co.'s shares have advanced 4.54% in the last one month and 4.10% in the previous three months. Additionally, from the beginning of 2014, the stock has gained 28.59%. The company's stock is trading above its 50-day and 200-day moving averages. Eli Lilly and Co.'s 50-day moving average of $63.27 is above its 200-day moving average of $58.79. Further, the stock traded at a PE ratio of 20.78 and has an RSI of 69.06. Free in depth research on LLY is available at:

www.Investor-Edge.com/LLY-26Sep2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED